# A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07231211/  
OnCo record `nct07231211` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Trastuzumab rezetecan in advanced solid tumours, run by Shanghai Shengdi Pharmaceutical Co., Ltd, now recruiting.

## Summary

A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07231211 by Shanghai Shengdi Pharmaceutical Co., Ltd, with 258 participants planned, started 2025-11-20 and due to reach its primary completion in 2026-10. Interventions recorded: SHR-4610 Injection and SHR-A1811 for injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07231211
- Phase: 1/2
- Setting: An Open-label, Multicenter Phase I/II Clinical Study of SHR-4610 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy
- Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd
- Enrolled: 258

## Sources

- ClinicalTrials.gov NCT07231211: https://clinicaltrials.gov/study/NCT07231211

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07231211.json